2 -Macroglobulin ( 2 -M), a major serum glycoprotein, has been implicated as a low-affinity binding protein for inhibin and activin. In serum, 2 -M exists as two major species, a native form that is abundant and stable, and a transformed ('fast') species that is rapidly cleared from the circulation via 2 -M receptors. In this study inhibin, activin and their major binding protein follistatin were investigated for their ability to bind to the native or transformed species of purified human 2 -M. Using native PAGE and size exclusion chromatography, radiolabelled inhibin, activin and follistatin bound to the transformed 2 -M. Inhibin and follistatin did not bind significantly to native 2 -M, whereas activin was able to bind to the native species but with a lower capacity compared with that to transformed 2 -M. Under reducing conditions, binding of these hormones to 2 -M was abolished. These findings implicate 2 -M as a mechanism whereby inhibin, activin and follistatin may be removed from the circulation through 2 -M receptors, but also whereby activin can be maintained in the circulation through its ability to bind to native 2 -M.
Introduction
2 -Macroglobulin ( 2 -M) is a major serum glycoprotein that has a multiplicity of functions including proteinase inhibition, immune regulation and cytokine binding (for review, see Chu & Pizzo 1994) . This 725 kDa protein exists in at least two major forms, a native or so-called 'slow' species, which is present in high concentrations in serum and can entrap proteinases, and the transformed or electrophoretically 'fast' species, which appears after trapping of a proteinase or reaction with primary amines (Van Leuven et al. 1981) . A number of growth factors have been shown to bind to 2 -M at a site distinct from that where proteinases are entrapped, including members of the transforming growth factor-(TGF ) superfamily (Chu & Pizzo 1994) . Importantly, some polypeptides have been shown to bind significantly only to the native form of 2 -M (e.g. carboxypeptidase A (Valnickova et al. 1996) ), to both forms (e.g. TGF 2 (Crookston et al. 1994) ), and some to only the transformed species (e.g. growth hormone (Kratzsch et al. 1995) ). The form of 2 -M to which factors can bind has significant implications for their physiology, as complexes of cytokines with native 2 -M remain stable in the circulation (Philip & O'Connor-McCourt 1991 , Crookston et al. 1993 , whereas factors binding to the transformed 2 -M are rapidly removed from the circulation via 2 -M receptors (Kristensen et al. 1990 , Strickland et al. 1990 , Misra et al. 1994 .
Inhibin and activin are members of the TGF superfamily with diverse physiological roles within the body (dePaolo et al. 1991 , Woodruff & Mather 1995 . Follistatin is a polypeptide that is structurally distinct from inhibin or activin and is able to bind these cysteine knot proteins with high affinity (Nakamura et al. 1990 , Kogawa et al. 1991 , Sugino et al. 1993 , Schneyer et al. 1994 . Investigations into high molecular mass binding proteins of inhibin and activin have implicated 2 -M (Schneyer et al. 1992 , Krummen et al. 1993 , Vaughan & Vale 1993 , but further characterizations of these interactions were not achieved in these earlier studies. More recently, Niemuller et al. (1995) demonstrated that activin A is able to bind to both the native and transformed 2 -M with a reported affinity of 510 60 and 190 30 n respectively. These data suggest that 2 -M has a dual function of both maintaining activin A in the circulation or within tissues and facilitating the clearance of activin A depending on the form of 2 -M present. Whether follistatin binds to 2 -M, and the different species of 2 -M that bind inhibin, have not been previously documented.
In this study, we have investigated the interactions of inhibin, activin and follistatin with the native and transformed conformations of 2 -M. The results, showing that inhibin and follistatin bind significantly only to the transformed species of 2 -M, whereas activin A binds to both the native and transformed species, suggest important regulatory mechanisms for these factors in terms of their availability at target tissues.
Materials and Methods

Purification of 2 -M
Human 2 -M was purified from time-expired plasma obtained from the South Melbourne Blood Bank using the method of Imber & Pizzo (1981) , and incorporating the modifications of Chu & Pizzo (1994) . Briefly, the plasma was filtered and the protein, remaining in solution in 4% polyethylene glycol 8000 but precipitated by 16% polyethylene glycol 8000, was then dialysed extensively against distilled water to separate any of the transformed 2 -M present. The resulting precipitate containing the transformed 2 -M was removed by centrifugation (7600 g for 30 min) and the supernatant was loaded on to a zinc chelate column. 2 -M has been shown to have a high affinity for metal ions, particularly copper and zinc (Porath et al. 1975) . The column was washed with phosphate buffers (0·1 mol/l phosphate-0·8 mol/l NaCl, pH 6·5, followed by 0·02 mol/l phosphate-0·15 mol/l NaCl, pH 6·0) until minimal protein was eluted from the column. In our hands, the 2 -M is eluted from the column with 0·05 mol/l EDTA-0·5 mol/l NaCl, pH 7·0. Fractions from the protein peak eluted under these conditions were subjected to native PAGE to assess the purity of the material, and compared with a commercially available preparation of human 2 -M (Calbiochem, San Diego, CA, USA). Those fractions containing the 2 -M were pooled, concentrated using an ultrafiltration cell, and stored at 80 C until further processing. Further purification was achieved using size exclusion chromatography on a Waters HPLC system. Aliquots of stored 2 -M material were chromatographed on a Superose 12 column (HR 10/30; Pharmacia Biotech, Uppsala, Sweden) in 0·05 mol/l PBS, pH 7·5, and fractions of the correct size for 2 -M (725 kDa) checked using native PAGE. This purification step removes low molecular mass contaminants and also monomer and dimer forms of 2 -M. Aggregated forms of 2 -M (>725 kDa) were difficult to remove from the preparation because of the poor discriminative power of this column for proteins of very high molecular mass. The activity of the purified native 2 -M was confirmed by reaction with trypsin and the demonstration of a shift to the transformed (proteinase-bound) species under native PAGE, and using a trypsin-binding assay (Bonner et al. 1992 , data not shown).
To convert 2 -M to the transformed species, native 2 -M was allowed to react with 300 mol/l methylamine hydrochloride (Sigma, St Louis, MO, USA) in 50 mol/l Tris, pH 8·2. After overnight incubation at room temperature, the reaction mixture was dialysed against 20 mol/l phosphate buffer, pH 7·4, overnight at 4 C. Transformation of the 2 -M was confirmed by native PAGE and the lack of binding to trypsin in the binding assay of Bonner et al. (1992) .
Hormone-2 -M incubations
The hormones tested for binding to 2 -M were bovine inhibin purified from follicular fluid, human recombinant activin A, bovine follistatin purified from follicular fluid, and human recombinant follistatin 288 kindly provided by the National Hormone and Pituitary Program (Baltimore, MD, USA). Iodinations were carried out using the chloramine T procedure for the inhibin as detailed by McLachlan et al. (1986) . For the activin and the two follistatin preparations, iodination was achieved with Iodogen (Pierce, Rockford, IL, USA) as described previously (Matteri et al. 1987) . The activin tracer was further purified by gel filtration using an Ultragel AcA54 column (90 2·5 cm; IBF Biotechnics, Villeneuve-laGarenne, France). In the experiments described, an aliquot of radiolabelled hormone (100 000 c.p.m.) was incubated with approximately 10 µg of either native or transformed 2 -M at 37 C, giving a concentration of 
PAGE
PAGE was performed using the Minigel apparatus (Hoeffer Scientific Instruments, San Francisco, CA, USA), using 5% acrylamide gels for native proteins (no dissociating agents) as previously described (Van Leuven et al. 1981) . Gels were routinely run at 20 mA for approximately 2 h. The transformed ('fast') 2 -M has a greater mobility under these conditions and thus can be discriminated from the native form. For PAGE in the presence of SDS, samples were prepared in buffer containing 1% SDS and were run on SDS-containing 5% polyacrylamide gels. Under reducing conditions, samples were prepared with 1% SDS and -mercaptoethanol, incubated at 90 C for 2 min, and run on SDS-containing 7·5% polyacrylamide gels. After electrophoresis, the gels were stained with Coomassie blue, destained, dried and, where appropriate, exposed to Biomax MR film (Kodak, Rochester, NY, USA). Radioactivity detected in the autoradiographs represents only hormone bound to 2 -macroglobulin. Gels containing 5-7·5% acrylamide resolve proteins of sizes greater than 75 kDa, whereas proteins smaller than 75 kDa, including the unbound hormones utilized in these studies, pass through the resolving gel and are not recoverable.
Size exclusion chromatography
Size exclusion chromatography of incubation mixtures containing radiolabelled hormones and 2 -M were performed using a BioSep Sec 2000 column (Phenomenex, Torrence, CA, USA) equilibrated with buffer, pH 6·8, containing 0·1 mol/l Na 2 SO 4 , 0·1 mol/l NaH 2 PO 4 and 0·05% BSA. The column had been calibrated with markers of known molecular mass using the equivalent buffer without BSA. For each hormone, column runs were with incubation mixtures containing radiolabelled hormone only, hormone and native 2 -M, and hormone and transformed 2 -M. Fractions were collected at 30 s intervals at a flow rate of 1 ml/min, and the radioactivity in each fraction was determined. To focus on the binding of radiolabelled hormone to 2 -M and to discount unlabelled tracer, the radioactivity in runs containing 2 -M was routinely expressed as a percentage of c.p.m. values measured in the equivalent fraction of the run containing labelled hormone only.
Results
Using both native PAGE and size exclusion chromatography, it was demonstrated that inhibin, activin and follistatin preferentially bound to the transformed conformation of 2 -M. After native PAGE, specific bands of radioactivity were detected in those lanes containing transformed 2 -M, but not in those containing native 2 -M (Fig. 1) . Some minor signal was present in all lanes above the position of tetrameric 2 -M, corresponding to aggregated 2 -M complexes that had not been removed during the purification process.
Size exclusion chromatography showed that radioactivity could be detected in the eluted fractions corresponding to the predicted position for 2 -M that preceded the peak of free labelled hormone (Fig. 2) . When profiles were expressed as a percentage of control runs to focus on the binding of 2 -M to the radiolabelled hormones (Fig. 3) , it was apparent that the inhibin and the two follistatin preparations bound significantly only to the transformed 2 -M, as also shown by native PAGE. However, with this more sensitive technique it was demonstrated that activin was able to bind to both forms of 2 -M, with a greater capacity for the transformed species. For activin, the percentage of tracer added that bound to 2 -M was 4·7 and 18% for the native and transformed conformations respectively. The percentage of tracer added that bound to transformed 2 -M was 12·0, 12·7 and 15·1% for human recombinant inhibin, bovine follistatin and human recombinant follistatin 288 respectively.
To investigate the nature of the binding of these hormones to 2 -M, PAGE under SDS and reducing conditions were performed. Under SDS non-reducing conditions, the 2 -M tetramer was broken down to dimeric and monomeric forms (Fig. 4) . In these subunit states, inhibin, activin and follistatin remained bound to transformed 2 -M. In addition, radioactive bands for activin were also detected for native 2 -M under SDS non-reducing conditions, with a lower intensity than that for transformed 2 -M. Trace amounts of the signal for radiolabelled inhibin and follistatin were found in the native 2 -M lanes, probably because of contamination of the native 2 -M with a proportion of the transformed species. When preformed radiolabelled ligand-2 -M complexes were run under reducing conditions, in which 2 -M is present predominantly in a monomeric form, radioactive bands were not detectable for any of the hormones (Fig. 5) . This result and the comparative result obtained under non-reducing conditions (Fig. 4) indicate that the ligand-2 -M complexes may involve a disulphide interchange which is reducible by -mercaptoethanol, rather than weak hydrophobic and electrostatic interactions between the radiolabelled hormones and 2 -M. 
Discussion
In this study we have determined that inhibin and follistatin bind significantly to the transformed 2 -M, whereas activin is able to bind to both species, but with a lesser capacity for the native (slow) species. The data for activin are consistent with those published by Niemuller et al. (1995) . Previous studies had implicated 2 -M as a binding protein for inhibin (Schneyer et al. 1992 , Krummen et al. 1993 , Vaughan & Vale 1993 , but without differentiating which species of 2 -M was the predominant binder.
The consequences of inhibin binding only to transformed 2 -M are highly relevant to the mechanism for removal of inhibin from the circulation. Receptors for 2 -M, the lipoprotein receptor-related protein, are found in many sites throughout the body (Moestrup et al. 1992) . A second 2 -M receptor has also been recently characterized on macrophages (Misra et al. 1994) . It is conceivable that by binding to transformed 2 -M, inhibin (and activin and follistatin) are being targeted to these tissues whereby they act through the 2 -M receptor. Nevertheless, when radiolabelled growth factors complexed to transformed 2 -M are injected into mice, over 50% of normalized radioactivity is recovered from the liver (LaMarre et al. 1991 , Philip & O'Connor-McCourt 1991 , Crookston et al. 1993 , Niemuller et al. 1995 . In the liver, 2 -Mproteinase complexes bind to receptors on hepatocytes, leading to endocytosis and degradation of the ligand (Gliemann & Davidsen 1986) . It is unclear whether 2 -M-growth factor complexes targeted to hepatocytes undergo a similar process of degradation, although recent evidence suggests that cytokines bound to transformed 2 -M may have intracellular actions after being internalized through the 2 -M receptor (Borth 1992 , Stouffer et al. 1993 .
Activin has been shown in this study and previously (Niemuller et al. 1995) to bind to both native and transformed 2 -M. Although activin binds with a lower capacity to the native conformation, this form is predominant in the circulation and is present in high abundance. As hypothesized by others (Schneyer et al. 1992 , Krummen et al. 1993 , Vaughan & Vale 1993 , Niemuller et al. 1995 , native 2 -M may play a role as a low-affinity carrier for activin in the circulation or within tissues where follistatin, a higher-affinity binding protein, is not abundant. The affinity of native 2 -M for activin has been estimated as 510 n (Niemuller et al. 1995) , whereas follistatin has an affinity for activin in the range 0·01-0·09 n (Nakamura et al. 1990 , Kogawa et al. 1991 , Sugino et al. 1993 , Schneyer et al. 1994 . Therefore consideration needs to be made at the tissue and circulatory level not only of the affinity of the binding proteins present, but also their relative abundance. We are currently exploring whether activin, when bound to 2 -M, can subsequently be released under conditions that favour binding to follistatin.
It is of interest that follistatin, a binding protein for inhibin and activin, was capable of binding to transformed 2 -M. We examined two preparations of follistatin, that purified from bovine follicular fluid and human recombinant follistatin 288; both were able to bind 2 -M with apparently similar capacities. This binding phenomenon may represent a mechanism whereby excess follistatin is removed from the circulation or follistatin is targeted to tissues expressing the 2 -M receptor. An intriguing question is whether complexes of activin and follistatin are able to bind to 2 -M. This process would be feasible if the binding domains for 2 -M on activin and follistatin are not masked after formation of activinfollistatin complexes. Although the binding domain for 2 -M on activin is almost certainly in an analogous position to that for TGF (Qian et al. 1992) , it is unclear if this site is involved in binding to follistatin. On the other hand, a binding site for 2 -M on the follistatin molecule has yet to be determined, although the regions responsible for binding to activin have been determined (Inouye et al. 1991 , Sumitomo et al. 1995 . It is important for these issues to be resolved, particularly the implications of whether follistatin-bound activin can or cannot be cleared via an 2 -M binding process.
In summary, inhibin, activin and follistatin were found to bind to the transformed species of 2 -M, with activin also binding to a lesser extent to the native form. The complexes were reversible, and as such provide potentially important mechanisms whereby these hormones can be distributed to various target tissues.
